Related Experiment Video
Updated: Apr 27, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.0K
Recombinant activated factor VII in clinical practice: a 2014 update.
Journal of Thrombosis and Thrombolysis
|July 13, 2014
Summary
Recombinant activated factor VII (rFVIIa) effectively treats bleeding in hemophilia and other bleeding disorders by enhancing thrombin generation. This review covers its mechanisms and clinical safety and efficacy in licensed uses.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Recombinant activated factor VII (rFVIIa) was developed for hemophilia with inhibitors.
- Its application expanded to other coagulopathies with impaired thrombin generation.
- Recent research clarifies rFVIIa's hemostatic mechanisms.
Purpose of the Study:
- To review the mechanisms of action of rFVIIa.
- To summarize clinical safety and efficacy data for licensed indications.
Main Methods:
- Literature review of rFVIIa mechanisms.
- Synthesis of clinical trial data and post-marketing surveillance.
Main Results:
- rFVIIa enhances thrombin generation, restoring hemostasis.
- Clinical data demonstrate safety and efficacy in acquired hemophilia, factor VII deficiency, and Glanzmann's thrombasthenia.
Conclusions:
- rFVIIa is a valuable therapeutic for specific coagulopathies.
- Understanding its mechanisms supports expanded clinical application and research.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.8K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
466
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
466
01:30Venous Thrombosis IV: Nursing Management
413
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
413